NCT00578370View on ClinicalTrials.gov

Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Psoriasis
Interventions
DRUG

Ciclosporin 0.5% (Formulation 01B)

Cutaneous emulsion 200µl once a day (26 days)

DRUG

Ciclosporin 1.5% (Formulation 02B)

Cutaneous emulsion 200µl once a day (26 days)

DRUG

0.1% betamethasone

Solution 200µl once a day (26 days)

DRUG

0.005% calcipotriol

Solution 200µl once a day (26 days)

DRUG

Formulation 00B

Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)

Trial Locations (1)

20095

Bioskin, Hamburg

All Listed Sponsors
lead

ISDIN

INDUSTRY

NCT00578370 - Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test | Biotech Hunter | Biotech Hunter